MX362403B - Compuestos triazolicos triciclicos como ligandos de receptores sigma. - Google Patents

Compuestos triazolicos triciclicos como ligandos de receptores sigma.

Info

Publication number
MX362403B
MX362403B MX2015014516A MX2015014516A MX362403B MX 362403 B MX362403 B MX 362403B MX 2015014516 A MX2015014516 A MX 2015014516A MX 2015014516 A MX2015014516 A MX 2015014516A MX 362403 B MX362403 B MX 362403B
Authority
MX
Mexico
Prior art keywords
ligans
sigma receptors
triazolic compounds
tricyclic triazolic
receptors
Prior art date
Application number
MX2015014516A
Other languages
English (en)
Other versions
MX2015014516A (es
Inventor
Carmen Almansa-Rosales
José-Luis Díaz-Fernández
Félix Cuevas-Cordobés
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MX2015014516A publication Critical patent/MX2015014516A/es
Publication of MX362403B publication Critical patent/MX362403B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

La presente invención se refiere a nuevos compuestos triazólicos tricíclicos que tienen una gran afinidad por receptores sigma, especialmente receptores sigma-1, así como al procedimiento para la preparación de los mismos, a composiciones que los comprenden y a su uso como medicamentos.
MX2015014516A 2013-04-19 2014-04-21 Compuestos triazolicos triciclicos como ligandos de receptores sigma. MX362403B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382143.9A EP2792679A1 (en) 2013-04-19 2013-04-19 Tricyclic triazolic compounds
PCT/EP2014/058036 WO2014170494A1 (en) 2013-04-19 2014-04-21 Tricyclic triazolic compounds as sigma receptors ligans

Publications (2)

Publication Number Publication Date
MX2015014516A MX2015014516A (es) 2016-02-09
MX362403B true MX362403B (es) 2019-01-15

Family

ID=48190443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014516A MX362403B (es) 2013-04-19 2014-04-21 Compuestos triazolicos triciclicos como ligandos de receptores sigma.

Country Status (32)

Country Link
US (1) US9512142B2 (es)
EP (2) EP2792679A1 (es)
JP (1) JP6337092B2 (es)
KR (1) KR102242405B1 (es)
CN (1) CN106029671B (es)
AR (1) AR095868A1 (es)
AU (1) AU2014255679B2 (es)
BR (1) BR112015026514B1 (es)
CA (1) CA2909735C (es)
CY (1) CY1119712T1 (es)
DK (1) DK2986616T3 (es)
ES (1) ES2628818T3 (es)
HK (1) HK1221226A1 (es)
HR (1) HRP20170949T1 (es)
HU (1) HUE034797T2 (es)
IL (1) IL242096B (es)
LT (1) LT2986616T (es)
MA (1) MA38523A1 (es)
MX (1) MX362403B (es)
MY (1) MY194093A (es)
PH (1) PH12015502407B1 (es)
PL (1) PL2986616T3 (es)
PT (1) PT2986616T (es)
RS (1) RS56114B1 (es)
RU (1) RU2666728C2 (es)
SG (1) SG11201508610QA (es)
SI (1) SI2986616T1 (es)
TN (1) TN2015000470A1 (es)
TW (1) TWI601733B (es)
UA (1) UA116015C2 (es)
WO (1) WO2014170494A1 (es)
ZA (1) ZA201507775B (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000064893A (ko) * 1996-07-20 2000-11-06 클래스 하인츠-게르트 트리아졸로퓨린,이의제조방법및이를함유하는약제학적제제
KR20040111324A (ko) * 2002-05-30 2004-12-31 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 트리사이클릭 파이라졸로트리아졸로피리미딘 링 구조를지닌 약제학적 활성화합물 및 사용 방법
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
PE20060653A1 (es) * 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
EP1849772A1 (en) * 2006-04-28 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
EP1921071A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
AU2009266806A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators

Also Published As

Publication number Publication date
KR20160025495A (ko) 2016-03-08
TWI601733B (zh) 2017-10-11
EP2986616B1 (en) 2017-03-29
CN106029671A (zh) 2016-10-12
HUE034797T2 (en) 2018-02-28
PH12015502407A1 (en) 2016-02-22
UA116015C2 (uk) 2018-01-25
CN106029671B (zh) 2018-10-12
CY1119712T1 (el) 2018-06-27
US20160060275A1 (en) 2016-03-03
ZA201507775B (en) 2017-09-27
SI2986616T1 (sl) 2017-09-29
SG11201508610QA (en) 2015-11-27
PT2986616T (pt) 2017-06-22
NZ713391A (en) 2020-11-27
PL2986616T3 (pl) 2017-10-31
ES2628818T3 (es) 2017-08-04
TN2015000470A1 (en) 2017-04-06
AU2014255679B2 (en) 2018-07-05
BR112015026514A2 (pt) 2017-07-25
AR095868A1 (es) 2015-11-18
RS56114B1 (sr) 2017-10-31
JP2016516799A (ja) 2016-06-09
MX2015014516A (es) 2016-02-09
CA2909735A1 (en) 2014-10-23
EP2792679A1 (en) 2014-10-22
AU2014255679A1 (en) 2015-11-05
HRP20170949T1 (hr) 2017-09-22
BR112015026514B1 (pt) 2022-09-13
KR102242405B1 (ko) 2021-04-21
PH12015502407B1 (en) 2016-02-22
EP2986616A1 (en) 2016-02-24
MA38523A1 (fr) 2017-03-31
RU2666728C2 (ru) 2018-09-12
DK2986616T3 (da) 2017-06-19
RU2015144720A (ru) 2017-05-24
HK1221226A1 (zh) 2017-05-26
TW201441232A (zh) 2014-11-01
LT2986616T (lt) 2017-07-10
MY194093A (en) 2022-11-11
IL242096B (en) 2019-05-30
WO2014170494A1 (en) 2014-10-23
CA2909735C (en) 2022-10-04
US9512142B2 (en) 2016-12-06
JP6337092B2 (ja) 2018-06-06

Similar Documents

Publication Publication Date Title
GEP20186921B (en) Pyrazolopyridines and pyrazolopyrimidines
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MY187449A (en) New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
GEP201706621B (en) Benzamides
MX2015010106A (es) Moduladores de la proteina activadora de 5-lipoxigenasa.
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
PH12016501169A1 (en) Fused imidazolyl derivatives, their preparation and use as medicaments
MX358721B (es) Derivados de indeno que tienen afinidad por el receptor sigma, su preparación y su uso como medicamentos.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
PH12017500005A1 (en) Tricyclic triazolic compounds
EA201591449A1 (ru) Способы получения противораковых композиций
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
PH12015502703A1 (en) Pharmaceutical compositions
IN2014MN01492A (es)
IN2015MN00068A (es)
PH12015502407B1 (en) Tricylic triazolic compounds as sigma receptors ligans

Legal Events

Date Code Title Description
FG Grant or registration